Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Key Highlights
- ➤EASI reduction 55% at Week 12 versus 22% placebo (p<0.01)
- ➤EASI-50 response 63% versus 23% placebo at Week 12
- ➤EASI-75 response 29% versus 9% placebo at Week 12
- ➤Phase 2b subcutaneous dose-ranging trial planned for mid-2027
- ➤Treatment-related adverse events 10.4% versus 13.6% placebo
Expert Statements
Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai
“Achieving rapid clinical responses with just two dose administrations demonstrates the distinct therapeutic potential of inhibiting IL-18.”
Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai
“Current biologic treatment options focus on addressing only the Th2 pathway, while EVO301 engages Th2 and additional pathways, offering a unique mechanism of action that could benefit a broad spectrum of patients in this highly heterogeneous disease.”
Eugene Bauer, Chief Medical Officer of Evommune
“EVO301 produced responses that kept improving for eight weeks following the final dose, with a safety and tolerability profile in line with placebo.”
Eugene Bauer, Chief Medical Officer of Evommune
“These data firmly establish EVO301 as a core component of our inflammatory disease pipeline and a potential option for patients living with AD, a disease with clear demand for more therapeutic options.”
Eugene Bauer, Chief Medical Officer of Evommune
“With strong clinical proof-of-concept now established, we are moving quickly to initiate a global Phase 2b trial that is dose-optimized with our subcutaneous formulation which is on track to begin in mid-2027.”
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
* Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitis * Biomarker analyses confirm robust Th2 pathway modulation, as well as broad anti-inflammatory activity across multiple inflammatory pathways (Th1, Th17/22) * Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027 Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna, Austria. EVO301 is a long-acting injectable fusion protein designed to selectively inhibit overactive IL-18, with the potential to offer broader upstream pathway control than standard-of-care biologics.
Get started
Create a free account to read the full story.